IOTA Pharmaceuticals


IOTA Pharmaceuticals
Fragment - based Drug Discovery
GBM Drug Bank
Glioma & Glioblastoma
WINDOW on Glioblastoma
About IOTA Pharmaceuticals

IOTA's Medicinal Chemistry is focused on translating fragment based chemical designs into optimised lead molecules for both IOTA's own drug discovery and our client-driven programmes. IOTA's integrated Drug Discovery Partnerships range from target-based hit discovery programmes to cell-based phenotypic screening campaigns.

IOTA's hit-to-lead efforts are headed by Dr Fredrik Svensson, and include structure-based design, exploratory medicinal chemistry and screening, as well as ADME-T optimization of resulting hits.

Further information about partnering with IOTA in specific Drug Discovery Partnerships can be obtained by contacting us on